Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment
Incyte's cancer drug fails trial, marking a major blow for immunotherapy combination treatment.
by Adam Feuerstein
Apr 06, 2018
2 minutes
The first real clinical test of the cancer immunotherapy combination thesis has come back negative.
Incyte said Friday that its experimental drug epacadostat failed to improve the efficacy of Merck’s checkpoint inhibitor Keytruda when the two drugs were used together to treat patients with newly diagnosed melanoma.
The negative outcome of the Incyte
You’re reading a preview, subscribe to read more.
Start your free 30 days